Adis summary of research: Safety, tolerability and pharmacokinetics of aripiprazole 2-monthly formulation in patients with schizophrenia or bipolar I disorder

The once-monthly long-acting injectable (LAI) formulation of aripiprazole, an atypical antipsychotic that stabilizes the dopamine-serotonin system, has a well-established efficacy and safety profile in schizophrenia and bipolar I disorder. This Adis Summary of Research reports the findings of a 32-week open-label trial assessing the safety, tolerability and pharmacokinetics of a new 2-monthly LAI formulation of aripiprazole in patients with schizophrenia or bipolar I disorder.